LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Venaxis, Inc. (“Venaxis” or the “Company”) (NASDAQ:APPY) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Venaxis concerning the Company’s operations and financial prospects.
Please contact Casey Sadler at 888-773-9224 or 310-201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Venaxis develops and commercializes products for unmet diagnostic and therapeutic needs. The Company’s lead product candidate is APPY1 − a blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. The investigation is related to the Company’s January 29, 2015, announcement that the U.S. Food and Drug Administration has determined that the Company’s appendicitis test was not found to be substantially equivalent to the standard of care. According to the Company, the FDA determined that “the APPY1 Test does not meet the criteria for substantial equivalence based upon data and information submitted by Venaxis in its 510(k) submission.”
If you purchased Venaxis securities, if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
